Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2026)

Catalyst Pharmaceuticals (CPRX) has 9 years of Net Margin data on file, last reported at 42.66% in Q1 2026.

• Quarterly Net Margin rose 254.0% year-over-year to 42.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.69% (up 178.0% YoY) and the FY2025 annual result came in at 38.03%, up 470.0% from the prior year.
• Net Margin advanced to 42.66% in Q1 2026, from 40.85% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 42.66% in Q1 2026 to a low of 29.96% in Q3 2023.
• A 5-year average of 31.55% and a median of 35.57% in 2025 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2023 — Net Margin tumbled 6970 bps — and 2024, when it surged 6406 bps.
• Tracing CPRX's Net Margin over 5 years: stood at 41.92% in 2022, then tumbled by 63 bps to 15.41% in 2023, then surged by 156 bps to 39.44% in 2024, then gained by 4 bps to 40.85% in 2025, then rose by 4 bps to 42.66% in 2026.
• The last three Net Margin figures came in at 42.66% (Q1 2026), 40.85% (Q4 2025), and 35.57% (Q3 2025), per Business Quant data.